Some people do well at 1.7 mg weekly, while others benefit from reaching the full 2.4 mg dose
The risk of developing these issues may go up the longer a person is on GLP-1 drugs
More research is needed to understand the mechanisms for how semaglutide improves kidney disease outcomes, but experts say treating obesity and type 2 diabetes has flow-on effects for the kidneys
Retatrutide research landscape and what it means for dosing Retatrutide is currently in Phase 3 clinical trials under the Eli Lilly TRIUMPH program
If you take BPC-157 via an injection, you may get: Itchiness, pain, or numbness at the injection site Vein, muscle, or skin discomfort Higher blood pressure Increased water retention Unintentional weight gain/loss Tiredness Who Can Benefit From BPC-157
Because GLP1 receptors influence satiety and reward processing, researchers hypothesize that GLP1 RAs might modify drinking behaviors